Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review

@article{Shimon2012PituitarydirectedMT,
  title={Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review},
  author={I. Shimon and Liat Rot and E. Inbar},
  journal={Pituitary},
  year={2012},
  volume={15},
  pages={608-613}
}
  • I. Shimon, Liat Rot, E. Inbar
  • Published 2012
  • Medicine
  • Pituitary
  • Hypercortisolism due to an ACTH-secreting pituitary adenoma (Cushing’s disease) is a chronic condition associated with high morbidity and mortality if inadequately managed. Pasireotide is a multireceptor-targeted somatostatin analogue and is the only approved medical therapy for Cushing’s disease that treats the underlying cause of the disorder. This paper reviews the available literature for medical-therapy-induced adenoma volume reduction in patients with Cushing’s disease and reports the… CONTINUE READING
    The Treatment of Cushing's Disease.
    • 60
    • Open Access
    Recent advances in the medical treatment of Cushing’s disease
    • 9
    • Open Access
    Update on medical treatment for Cushing’s disease
    • 23
    • Open Access

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 28 REFERENCES
    Cushing's syndrome
    • 794
    Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.
    • 474
    • Highly Influential
    • Open Access
    Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.
    • 195
    • Open Access
    Pituitary-targeted medical therapy of Cushing's disease
    • 9
    The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas.
    • 170
    • Open Access